Skye Bioscience Inc (SKYE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2015 | 12-2014 | 12-2013 | 10-2013 | 12-2012 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -4,841 | -2,734 | -120 | -4 | N/A |
| Depreciation Amortization | 595 | 2 | N/A | 11 | 0 |
| Accounts receivable | N/A | N/A | N/A | -18 | N/A |
| Accounts payable and accrued liabilities | -274 | 407 | N/A | N/A | N/A |
| Other Working Capital | -419 | 500 | 120 | -23 | -3 |
| Other Operating Activity | 1,211 | 70 | 0 | 20 | 0 |
| Operating Cash Flow | $-3,728 | $-1,755 | $N/A | $-15 | $-3 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -2 | -23 | N/A | -38 | 0 |
| Investing Cash Flow | $-2 | $-23 | $N/A | $-38 | $0 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | 32 | N/A |
| Debt Repayment | N/A | N/A | N/A | -10 | N/A |
| Common Stock Issued | 721 | 1,986 | N/A | 49 | N/A |
| Other Financing Activity | 6,023 | 0 | 0 | 8 | 11 |
| Financing Cash Flow | $6,744 | $1,986 | $N/A | $78 | $11 |
| Beginning Cash Position | 207 | N/A | N/A | 26 | N/A |
| End Cash Position | 3,221 | 207 | N/A | 52 | N/A |
| Net Cash Flow | $3,014 | $207 | $N/A | $26 | $8 |
| Free Cash Flow | |||||
| Operating Cash Flow | -3,728 | -1,755 | N/A | -15 | -3 |
| Capital Expenditure | -2 | -23 | N/A | -49 | N/A |
| Free Cash Flow | -3,730 | -1,779 | 0 | -64 | -3 |